Leave Your Message

Submit An Free Inquiry

Our medical team will make an evaluation for you, based on the information you provided. This procedure is free of charge.

AI Helps Write
AI Helps Write

Ọmụmụ Ihe Mmalite Na-akwado Nchekwa na Irè nke CD19/CD20 Ọgwụgwọ CAR-T maka r/r B-NHL

2025-01-23

Ọmụmụ ihe ọhụrụ e bipụtara na Ọbarana-egosipụta mmepe gara nke ọma nke prizloncabtagene autoleucel (prizlon-cel), ọgwụgwọ mkpụrụ ndụ CAR-T ọhụrụ nke CD19/CD20 na-elekwasị anya, maka ịgwọ mkpụrụ ndụ B na-alaghachi azụ/na-anaghị eguzogide mmeghachi omume, maka ọgwụgwọ mkpụrụ ndụ B na-alaghachi azụ/na-anaghị eguzogide mmeghachi omume. Lymphoma na-abụghị Hodgkin (r/r B-NHL). Nnwale a, nke bụ ọmụmụ ihe nkebi nke 1, nke e mere na mba Chaịna n'ọtụtụ ebe, nke e ji akara mepere emepe, na-enye data dị mma gbasara nchekwa na ịdị irè nke ụzọ a nke nwere ebumnuche abụọ.

Ndị otu ndị nchọpụta a ma ama sitere na ụlọ ọrụ dịka Ụlọ Ọgwụ Mbụ nke Mahadum Zhejiang na Mahadum Tongji duziri ọmụmụ ihe a, ndị ọrịa 48 nwere r/r B-NHL, nke buru ibu karịa. B-Cell Lymphoma (LBCL). Ndị ọrịa agafeela usoro ọgwụgwọ atọ mbụ. Ndị sonyere natara otu ọgwụ prizlon-cel mgbe ha gbasịrị ọgwụ chemotherapy nke lymphodepleting, yana usoro ọgwụgwọ dị n'ọkwa atọ (DL1, DL2, na DL3).

Nchọpụta Ndị Dị Mkpa:

  • Profaịlụ Nchekwa: Ahụghị ihe ndị na-egbochi ọgwụ (DLT), ọgwụgwọ ahụ gosikwara mmetụta ndị a na-apụghị ịchịkwa. Cytokine release syndrome (CRS) mere na 93.8% nke ndị ọrịa, ọkachasị ndị nọ na ọkwa 1-2, naanị otu onye ọrịa nọ na ọkwa 3. Ọrịa neurotoxicity nke metụtara mkpụrụ ndụ ihe nketa (ICANS) dị ụkọ ma dịkwa obere, enweghịkwa ihe omume ọkwa 3 ma ọ bụ karịa.
  • Arụmọrụ: E nwetara ọnụego nzaghachi zuru oke (ORR) nke 91.5%, yana ọnụego nzaghachi zuru oke (CR) nke 85.1%. N'ime ndị ọrịa LBCL, ọnụego ORR na CR bụ 90.7% na 86.0%, n'otu n'otu. Ihe dị ịtụnanya bụ na 48.9% nke ndị ọrịa nọgidere na-enwe CR na nsochi ikpeazụ, yana ụfọdụ nzaghachi gafere afọ atọ.
  • Nsonaazụ Nlanarị: Atụmatụ Kaplan-Meier gosiri na afọ abụọ nke nzaghachi (DOR), ndụ na-enweghị ọganihu (PFS), na ọnụego ndụ zuru oke (OS) nke 66.0%, 62.6%, na 76.5%, n'otu n'otu. N'ime ndị ọrịa CR, ọnụego ndị a dị elu karịa.

Prizlon-cel gosipụtara mmụba siri ike na ntachi obi ogologo oge, yana oge mgbake nke mkpụrụ ndụ B nke ụbọchị 185. Nhazi ya nke ezubere iche na-edozi mgbapụ antigen, usoro mgbochi a na-ahụkarị na ọgwụgwọ CAR-T.